SIGNAL-DRIVEN SALES

Turn Funding Signals into Pipeline

Fundz analyzes real-time funding events through YOUR lens to surface companies most likely to buy — with the “why now” built in.

10–25 ICP-matched leads daily • Buyer-intent scoring • No duplicates

Every plan includes:

✓Signal-Driven Leads Based on YOUR ICP

✓Slack + Chrome real-time alerts

✓No duplicates — only new events

INDUSTRY FIRST

Engine Biosciences Announces $43 Million Series A Round To Decipher Genetic Codes For New Medicines Through Machine Learning And Next-Generation Combinatorial Genetics

May 26, 2021•over 4 years ago

Amount Raised

$43 Million

Round Type

series a

Description

Engine Biosciences (“Engine”) today announced the successful completion of an oversubscribed $43 million Series A funding round. Engine identifies errors in the complex genetic codes of diseases, fixing them with precise therapeutic solutions. This round was led by Polaris Partners and also included new investors Invus and one of the world’s premier institutional investors, based in Singapore. Existing investors also participated in the Series A, which included 6 Dimensions Capital, WuXi AppTec, DHVC, EDBI, Baidu Ventures, Vectr Ventures, Goodman Capital, WI Harper, and Nest.Bio

Company Information

Company

Engine Biosciences

About

Engine Biosciences is a venture-backed Singapore- and Silicon Valley-based company deciphering complex biology to unleash many impactful medicines. Our proprietary NetMAPPR platform integrates data science and machine learning, high-throughput biological experiments using our patented CombiGEM combinatorial genetics system, computational and wet lab chemistry, and drug discovery. We systematically analyze biological networks comprising millions-to-billions of gene interactions at greater speed and scale than conventionally possible, yielding promising drug targets for specific patient populations. Led by drug discovery and technology industry veterans and scientific pioneers, we are developing our growing pipeline of precision oncology therapeutics and working with partners to expand our impact. For more information, please visit www.enginebio.com

Company News

(6 articles)

Wed, 30 Apr 2025 07:00:00 GMT

Engine Biosciences Appoints Renowned Drug Discovery and Development Leader Robert Abraham, PhD, as Chief Scientific Officer - PR Newswire

Tue, 31 Oct 2023 07:00:00 GMT

Engine Biosciences Secures $27 Million Series A Extension to Advance Development of Precision Oncology Medicines and Novel Biomarkers for Patient Selection - Business Wire

Tue, 08 Apr 2025 07:00:00 GMT

Engine Biosciences and Experimental Drug Development Centre Partner to Advance Novel Therapies to Combat Cancer - PR Newswire

Wed, 26 May 2021 07:00:00 GMT

Engine Biosciences Announces $43 Million Series A Round to Decipher Genetic Codes for New Medicines Through Machine Learning and Next-Generation Combinatorial Genetics - Business Wire

Wed, 31 Jan 2018 08:00:00 GMT

Engine Biosciences Raises $10 Million in Seed Financing to Accelerate Drug Discovery Using Genomics and Artificial Intelligence - PR Newswire

Wed, 31 Jan 2018 08:00:00 GMT

Drug-discovery startup Engine raises $10m in record-breaking seed round - Tech in Asia

FundzWatch™ Score

Medium Activity

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech